Platelet Phenotype and Function Changes With Increasing Duration of Extracorporeal Membrane Oxygenation
- 12 January 2022
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Critical Care Medicine
- Vol. 50 (8), 1236-1245
- https://doi.org/10.1097/ccm.0000000000005435
Abstract
Objectives: To investigate platelet pathophysiology associated with pediatric extracorporeal membrane oxygenation (ECMO). Design: Prospective observational study of neonatal and pediatric ECMO patients from September 1, 2016, to December 31, 2019. Setting: The PICU in a large tertiary referral pediatric ECMO center. Patients: Eighty-seven neonates and children (< 18 yr) supported by ECMO. Interventions: None. Measurements and Main Results: Arterial blood samples were collected on days 1, 2, and 5 of ECMO and were analyzed by whole blood flow cytometry. Corresponding clinical data for each patient was also recorded. A total of 87 patients were recruited (median age, 65 d; interquartile range [IQR], 7 d to 4 yr). The median duration of ECMO was 5 days (IQR, 3–8 d) with a median length of stay in PICU and hospital of 18 days (IQR, 10–29 d) and 35 days (IQR, 19–75 d), respectively. Forty-two patients (48%) had at least one major bleed according to a priori determined definitions, and 12 patients (14%) had at least one thrombotic event during ECMO. Platelet fibrinogen receptor expression decreased (median fluorescence intensity [MFI], 29,256 vs 26,544; p = 0.0005), while von Willebrand Factor expression increased (MFI: 7,620 vs 8,829; p = 0.0459) from day 2 to day 5 of ECMO. Platelet response to agonist, Thrombin Receptor Activator Peptide 6, also decreased from day 2 to day 5 of ECMO, as measured by binding with anti-P-selectin, PAC-1 (binds activated GPIIb/IIIa), and anti-CD63 monoclonal antibodies (P-selectin area under the curve [AUC]: 63.46 vs 42.82, respectively, p = 0.0022; PAC-1 AUC: 93.75 vs 74.46, p = 0.0191; CD63 AUC: 55.69 vs 41.76, p = 0.0020). Conclusions: The loss of platelet response over time may contribute to bleeding during ECMO. These novel insights may be useful in understanding mechanisms of bleeding in pediatric ECMO and monitoring platelet markers clinically could allow for prediction or early detection of bleeding and thrombosis.This publication has 41 references indexed in Scilit:
- Age-Based Difference in Activation Markers of Coagulation and Fibrinolysis in Extracorporeal Membrane OxygenationPediatric Critical Care Medicine, 2014
- Perioperative mechanical circulatory support in children: An analysis of the Society of Thoracic Surgeons Congenital Heart Surgery DatabaseThe Journal of Thoracic and Cardiovascular Surgery, 2013
- Developmental hemostasis: age‐specific differences in the levels of hemostatic proteinsJournal of Thrombosis and Haemostasis, 2013
- First Report of Elevated Monocyte-Platelet Aggregates in Healthy ChildrenPLOS ONE, 2013
- Testing Platelet FunctionHematology/Oncology Clinics of North America, 2013
- Understanding and Evaluating Platelet FunctionHematology, 2010
- Effect of preextracorporeal membrane oxygenation ventilation days and age on extracorporeal membrane oxygenation survival in critically ill childrenJournal of Pediatric Surgery, 2009
- Indices of platelet activation and the stability of coronary artery diseaseJournal of Thrombosis and Haemostasis, 2007
- Developmental haemostasisThrombosis and Haemostasis, 2006
- In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function.Proceedings of the National Academy of Sciences of the United States of America, 1996